TheraKine has developed a novel, proprietary platform drug-delivery technology to deliver biologics and small molecule inhibitors. Linear release with durations of weeks to months are now possible using TheraKine’s tunable, sustained-release technology. This enables resorbable implants in gel or pellet form, making them compatible with injection or catheter delivery.
TheraKine's technology uses existing GRAS excipients for minimum regulatory complexity.
TheraKine's lead technology application is for inflammatory and degenerative diseases of the eye. Each of us knows someone with an Inflammatory, Diabetic or Degenerative Eye Disease. Current treatments for some of these diseases are ineffective, and have side effects that can be as bad, or worse than the disease. Injection of biologics has shown good results in AMD, but monthly injections are the rule. TheraKine's lead candidates thus tackle a significant medical problem and provide technology validation.
We recognize that inflammation is the common cause of vision loss in many serious eye diseases. Our lead technology applications attack inflammation by using clinically proven biologic drugs, delivered to the surface or inside the eye, with biologic drugs specifically selected to target inflammation with minimum complications.